KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.

摘要: Background. Screening for colorectal cancer (CRC) requires non-invasive methods of high diagnostic sensitivity and specificity. We evaluated the measurement genetic protein biomarkers CRC in stool samples with aim testing their clinical utility a screening program. Patients methods. Individuals aged 53-75 years who were at risk im munochemical fecal occult blood test (iFOBT) positive invited to submit molecular prior colonoscopy. KRAS codon 12 Gly →Asp, Gly, Val, 13 →Cys gene mutations tested using an in-house real-time ARMS PCR method. M2PK levels measured utilizing com mercial ELISA kit. Results. At colonoscopy, 7.6% patients found have CRC, 50% had adeno mas, 10.6% hyperplastic polyps, 20.2% diverticulosis hemorrhoids, 11.6% normal mucosa. The best (50%) was those cas es where abnormalities coexisted. showed detection rate 40.3% adenomas but combination only 5.7% ( P <0.01). iFOBT false 31.8% cases which colonoscopy excluded neoplastic lesions, while coexistence molecu lar enzymatic more specific rates between 8.3% 9.0% <0.05). Conclusion. Our approach demonstrates that can cer-associated iFOBT-positive could help sep arate true from positives FOBT-based process. par